Advertisement
RGEN vs WAT
Which Stock Would AI Choose? Repligen (RGEN) vs. Waters (WAT) Stock Comparison
Key Takeaways
- Repligen (RGEN) is a bioprocessing pure-play growing roughly 15% annually, while Waters (WAT) is a larger, diversified analytical-instruments leader growing in the high single digits.
- Waters recently completed a transformative acquisition of Becton Dickinson's Biosciences and Diagnostic Solutions business, roughly doubling its projected 2026 revenue scale.
- Repligen's relative performance has lagged its industry over the past six months, whereas Waters has drawn a mix of upgraded ratings and hold/equal-weight calls.
- The two companies serve different parts of the life-sciences value chain, making this a contrast of growth velocity versus scale and diversification.
- Both businesses are levered to biopharma spending, though Waters adds meaningful industrial, food, and environmental end-market exposure.
Introduction
Life-science tools companies sit at the intersection of biotechnology innovation and recurring consumables revenue, making them closely watched by both growth and quality-oriented investors. RGEN and WAT operate in this space but pursue very different strategies. Repligen concentrates on bioprocessing technologies used to manufacture biologic drugs, while Waters dominates analytical instruments such as liquid chromatography and mass spectrometry. For traders evaluating relative performance and market positioning, this stock comparison offers a useful lens on two distinct risk-and-reward profiles: a faster-growing niche specialist versus a scaled, diversified platform undergoing a major acquisition-driven transformation.
RGEN Overview and Recent Performance
RGEN, or Repligen Corporation, develops and sells bioprocessing technologies across filtration and fluid management, chromatography, process analytics, and proteins. Its customers are primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs, companies that manufacture drugs on behalf of drug sponsors). In recent weeks, Repligen reported fourth-quarter revenue of roughly $198 million, up about 18% year over year, capping a full-year 2025 revenue total of approximately $738 million and about 16% annual growth. Adjusted earnings per share (EPS) of $1.71 for 2025 represented an increase from $1.58 a year earlier.
Sentiment has been supported by strong order trends and a record quarter for process-analytics equipment placements, alongside new product launches. However, the stock's relative performance has trailed its industry, rising about 11% over the past six months versus a broader industry gain of roughly 23%. For 2026, management has guided revenue to a range of $810 million to $840 million and adjusted EPS of $1.93 to $2.01, reflecting continued above-market growth ambitions tempered by a gene-therapy customer headwind in the first half.
WAT Overview and Recent Performance
WAT, or Waters Corporation, is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for more than 65 years. Its product portfolio centers on liquid chromatography and mass spectrometry instruments, chemistry consumables, and services, with pharmaceutical customers representing roughly 58% of revenue. In recent market activity, Waters delivered fourth-quarter net sales of about $932 million, up 7% year over year, and full-year 2025 sales of approximately $3.17 billion, also up about 7%.
Momentum has been driven by high-volume testing opportunities in GLP-1 (glucagon-like peptide-1) therapeutics, PFAS (per- and polyfluoroalkyl substances) testing, and generic-drug manufacturing, along with strong adoption of its flagship Alliance iS platform. The most significant recent development is the completion of its acquisition of Becton Dickinson's Biosciences and Diagnostic Solutions business, which materially expands scale. Reflecting that combination, Waters has guided total 2026 revenue to roughly $6.4 billion and non-GAAP (non-GAAP, meaning adjusted, non-Generally Accepted Accounting Principles) EPS to $14.30 to $14.50.
Trending AI Robots
For traders seeking a systematic edge in this comparison, Tickeron's Trending AI Robots page curates a selection of its AI trading bots, each configured with distinct trading styles, strategies, timeframes, performance statistics, and sets of tickers. Tickeron offers hundreds of AI trading bots that collectively trade thousands of different tickers, but only those best suited to current market conditions earn a place in this featured section. Because these bots vary widely in approach, risk profile, and historical results, the page gives investors a way to evaluate algorithmic strategies rather than relying on manual screening alone. Reviewing the featured robots can help you identify signals aligned with your own time horizon and risk tolerance.
Head-to-Head Comparison
Although both companies sell into biopharma, their business models diverge sharply. RGEN is a bioprocessing specialist with higher organic growth, roughly 15% to 16% in 2025, and a consumables-heavy model that generates recurring demand as biologic drugs scale into production. Its smaller size and narrower focus, however, concentrate risk around biotech funding cycles and individual customer programs. In contrast, WAT offers slower but steadier high-single-digit growth spread across a diversified installed base of instruments, consumables, and services, plus meaningful industrial and environmental exposure.
The risk profiles also differ. Waters carries acquisition-related integration risk and increased financial leverage following its large BD Biosciences transaction, while Repligen faces a modest but real gene-therapy headwind and valuation sensitivity to growth expectations. On sentiment, Waters has attracted a mix of upgrades and hold/equal-weight ratings as the market weighs the value of its transformation, whereas Repligen holds a broadly constructive analyst consensus with an average price target above its recent price.
Tickeron AI Verdict
Based on observable trend consistency, relative positioning, and near-term catalysts, Tickeron's AI would likely tilt toward RGEN for traders prioritizing momentum and organic growth velocity, given its double-digit revenue expansion, record equipment placements, and above-market guidance. Conversely, for investors emphasizing scale, diversification, and post-acquisition earnings accretion, WAT may present the more balanced risk-reward profile. The ultimate signal depends on whether an algorithm weights growth consistency or structural diversification more heavily; both stocks present defensible but distinct cases in the current market environment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RGEN is a Hold and WAT is a StrongBuy.
RGEN in downward trend: price dove below 50-day moving average on November 10, 2026
RGEN moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend. In 38 of 41 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 57 cases where RGEN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 75%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RGEN as a result. In 65 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
The Moving Average Convergence Divergence Histogram (MACD) for RGEN turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 42 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
Bullish Trend Analysis
The 10-day moving average for RGEN crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.
Following a +6.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where RGEN advanced for three days, in 226 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
RGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. RGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.636) is normal, around the industry mean (4.964). RGEN has a moderately high P/E Ratio (234.446) as compared to the industry average of (40.591). Projected Growth (PEG Ratio) (1.935) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (12.469) is also within normal values, averaging (56.876).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Momentum Indicator for WAT turns positive, indicating new upward trend
WAT saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 92 similar instances where the indicator turned positive. In 60 of the 92 cases, the stock moved higher in the following days. The odds of a move higher are at 65%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for WAT just turned positive on November 10, 2026. Looking at past instances where WAT's MACD turned positive, the stock continued to rise in 27 of 46 cases over the following month. The odds of a continued upward trend are 59%.
Following a +5.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where WAT advanced for three days, in 179 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
The Aroon Indicator entered an Uptrend today. In 118 of 207 cases where WAT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 57%.
Bearish Trend Analysis
The 10-day RSI Indicator for WAT moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In 23 of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at 68%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 70 cases where WAT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 64%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where WAT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 62%.
WAT broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 12 (best 1 - 100 worst), indicating outstanding price growth. WAT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 46 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock slightly better than average.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.959) is normal, around the industry mean (67.298). WAT has a moderately high P/E Ratio (114.975) as compared to the industry average of (4.239). Projected Growth (PEG Ratio) (1.649) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (6.752) is also within normal values, averaging (9.775).
The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
RGEN | WAT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 71 | 26 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 99 Overvalued | 88 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 46 | |
SMR RATING 1..100 | 88 | 89 | |
PRICE GROWTH RATING 1..100 | 39 | 12 | |
P/E GROWTH RATING 1..100 | 97 | 2 | |
SEASONALITY SCORE 1..100 | 90 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
WAT's Valuation (88) in the Medical Specialties industry is in the same range as RGEN (99) in the Biotechnology industry. This means that WAT’s stock grew similarly to RGEN’s over the last 12 months.
WAT's Profit vs Risk Rating (46) in the Medical Specialties industry is somewhat better than the same rating for RGEN (100) in the Biotechnology industry. This means that WAT’s stock grew somewhat faster than RGEN’s over the last 12 months.
RGEN's SMR Rating (88) in the Biotechnology industry is in the same range as WAT (89) in the Medical Specialties industry. This means that RGEN’s stock grew similarly to WAT’s over the last 12 months.
WAT's Price Growth Rating (12) in the Medical Specialties industry is in the same range as RGEN (39) in the Biotechnology industry. This means that WAT’s stock grew similarly to RGEN’s over the last 12 months.
WAT's P/E Growth Rating (2) in the Medical Specialties industry is significantly better than the same rating for RGEN (97) in the Biotechnology industry. This means that WAT’s stock grew significantly faster than RGEN’s over the last 12 months.
| RGEN | WAT | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 68% |
| Stochastic ODDS (%) | 2 days ago 75% | 2 days ago 64% |
| Momentum ODDS (%) | 2 days ago 73% | 2 days ago 65% |
| MACD ODDS (%) | 2 days ago 81% | 2 days ago 59% |
| TrendWeek ODDS (%) | 2 days ago 80% | 2 days ago 66% |
| TrendMonth ODDS (%) | 2 days ago 73% | 2 days ago 64% |
| Advances ODDS (%) | 3 days ago 73% | 3 days ago 65% |
| Declines ODDS (%) | 7 days ago 81% | 10 days ago 62% |
| BollingerBands ODDS (%) | 2 days ago 77% | 2 days ago 63% |
| Aroon ODDS (%) | N/A | 2 days ago 57% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
RGEN’s FA Score shows that 0 FA rating(s) are green while WAT’s FA Score has 2 green FA rating(s).
- RGEN’s FA Score: 0 green, 5 red.
- WAT’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
RGEN’s TA Score shows that 3 TA indicator(s) are bullish while WAT’s TA Score has 4 bullish TA indicator(s).
- RGEN’s TA Score: 3 bullish, 5 bearish.
- WAT’s TA Score: 4 bullish, 4 bearish.
Price Growth
RGEN (@Pharmaceuticals: Other) experienced а -2.41% price change this week, while WAT (@Medical Specialties) price change was +3.40% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.01%. For the same industry, the average monthly price growth was +6.28%, and the average quarterly price growth was +22.46%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -4.83%. For the same industry, the average monthly price growth was -5.05%, and the average quarterly price growth was +38.44%.
Reported Earning Dates
RGEN is expected to report earnings on Feb 24, 2027.
WAT is expected to report earnings on Feb 17, 2027.
Industries' Descriptions
@Pharmaceuticals: Other (+2.01% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical Specialties (-4.83% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
RGEN and
Correlation & Price change
A.I.dvisor indicates that over the last year, RGEN has been closely correlated with DHR. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if RGEN jumps, then DHR could also see price increases.
| Ticker / NAME | Correlation To RGEN | 1D Price Change % | ||
|---|---|---|---|---|
| RGEN | 100% | -2.77% | ||
| DHR - RGEN | 67% Closely correlated | +0.42% | ||
| A - RGEN | 65% Loosely correlated | -1.27% | ||
| BIO - RGEN | 60% Loosely correlated | -0.47% | ||
| MTD - RGEN | 59% Loosely correlated | -0.62% | ||
| TMO - RGEN | 58% Loosely correlated | -0.48% | ||
More | ||||
WAT and
Correlation & Price change
A.I.dvisor indicates that over the last year, WAT has been closely correlated with A. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if WAT jumps, then A could also see price increases.
| Ticker / NAME | Correlation To WAT | 1D Price Change % | ||
|---|---|---|---|---|
| WAT | 100% | -0.25% | ||
| A - WAT | 67% Closely correlated | -1.27% | ||
| RVTY - WAT | 60% Loosely correlated | -1.01% | ||
| TMO - WAT | 60% Loosely correlated | -0.48% | ||
| BRKR - WAT | 58% Loosely correlated | -6.46% | ||
| RGEN - WAT | 56% Loosely correlated | -2.77% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| LOPP | 36.48 | N/A | N/A |
| Gabelli Love Our Planet & People ETF (LOPP) | |||
| CGDV | 48.48 | -0.03 | -0.06% |
| Capital Group Dividend Value ETF (CGDV) | |||
| HTAB | 18.57 | -0.08 | -0.43% |
| Hartford Schroders Tax-Aware Bond ETF (HTAB) | |||
| XVV | 57.08 | -0.34 | -0.59% |
| iShares ESG Select Screened S&P 500 ETF (XVV) | |||
| OVF | 29.63 | -0.21 | -0.71% |
| Overlay Shares Foreign Equity ETF (OVF) | |||